Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5656187 | HPB | 2017 | 6 Pages |
Abstract
Neoadjuvant therapy appeared to be safe prior to operative intervention as no difference in overall postoperative morbidity or mortality rates were identified. There were increased intra/postoperative transfusions in the neoadjuvant therapy group, but neoadjuvant therapy was associated with lower rates of pancreatic fistulas.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Nicholas M. Czosnyka, Andrew J. Borgert, Travis J. Smith,